Sandra Charvatova

Ostrava, MO, Czech Republic

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Winners take it all: turning cell competition into a therapeutic ally.

Winners take it all: turning cell competition into a therapeutic ally.

Journal: Cell communication and signaling : CCS
Published: August 22, 2025

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Composition and Functional State of T and NK Cells in the Extramedullary Myeloma Tumor Microenvironment.

Journal: Blood cancer discovery
Published: May 15, 2025

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies.

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies.

Journal: Blood cancer journal
Published: June 20, 2024

NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment.

NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment.

Journal: Cells
Published: August 21, 2023

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.

Journal: Journal of translational medicine
Published: February 08, 2023

Novel Local "Off-the-Shelf" Immunotherapy for the Treatment of Myeloma Bone Disease.

Novel Local "Off-the-Shelf" Immunotherapy for the Treatment of Myeloma Bone Disease.

Journal: Cells
Published: December 08, 2022

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy.

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 10, 2022

Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.

Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.

Journal: Cells
Published: March 07, 2021

A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers.

A Bird's-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers.

Journal: Cancers
Published: April 14, 2020
Showing 1-9 of 9

Last Updated: 09/26/2026